Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases

– Proceeds to support the development of Eccogene’s clinical-stage metabolic pipeline including ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disorders BOSTON and SHANGHAI, June 11, 2023 /PRNewswire/ — Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic … Read more